Drug Profile
Research programme: siRNA and bionanotechnology therapies - ViRexx
Alternative Names: Bionanoparticles - ViRexx; siRNA - ViRexxLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ViRexx Medical Corp
- Developer Endo International; National Institute for Nanotechnology; Paladin Labs
- Class Small interfering RNA
- Mechanism of Action Immunomodulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C
- Discontinued Immunological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Hepatitis-B in Canada
- 04 Nov 2017 No recent reports of development identified for research development in Hepatitis-C in Canada
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International